Literature DB >> 29296931

Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study.

Sigrun Thorsteinsdottir1,2, Sigrun H Lund2, Ebba K Lindqvist3, Marianna Thordardottir2, Gunnar Sigurdsson4, Rene Costello5, Debra Burton5, Hlif Steingrimsdottir1, Vilmundur Gudnason2,4, Gudny Eiriksdottir4, Kristin Siggeirsdottir4, Tamara B Harris6, Ola Landgren7, Sigurdur Y Kristinsson1,2.   

Abstract

Previous studies have shown that individuals with monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of fractures, although the underlying mechanisms remain unknown. Our aim was to analyze bone mineral density (BMD), bone volume, and risk of fractures among individuals with MGUS. We performed a screening using the Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study cohort, consisting of 5764 elderly individuals, identifying 300 individuals with MGUS, and 275 with light-chain MGUS. Quantitative computerized tomography was performed in the lumbar spine and hip to evaluate BMD and bone geometry. Analysis of variance and the Tukey honest significance test were used to compare the groups. Hospital records were used to record fractures, with a mean follow-up of 6.9 years. Cox proportional hazard was used to compare fracture risk. No difference was found in BMD between subjects with MGUS and others in the spine (P = .34) or in total hip (P = .30). Individuals with MGUS had a significant increase in bone volume compared with others in the spine (P < .001) and total hip (P < .001). Overall, the risk of fractures was not significantly increased in individuals with MGUS (hazard ratio [HR], 1.19; 95% confidence interval [CI], 0.94-1.50). Men with MGUS had a significantly increased fracture risk, compared with other men (HR, 1.46; 95% CI, 1.03-2.08). Our results show that although individuals with MGUS do not have decreased BMD, bone volume is increased, and MGUS men have a 50% increased fracture risk. These results indicate that bone disease and fractures in MGUS differ from processes known from osteoporosis.

Entities:  

Year:  2017        PMID: 29296931      PMCID: PMC5745135          DOI: 10.1182/bloodadvances.2017010454

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  35 in total

1.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

2.  Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study.

Authors:  Bo Abrahamsen; Ivan Andersen; Susanne S Christensen; Jonna Skov Madsen; Kim Brixen
Journal:  BMJ       Date:  2005-03-14

3.  Effects of age and sex on the strength and cortical thickness of the femoral neck.

Authors:  R D Carpenter; S Sigurdsson; S Zhao; Y Lu; G Eiriksdottir; G Sigurdsson; B Y Jonsson; S Prevrhal; T B Harris; K Siggeirsdottir; V Guðnason; T F Lang
Journal:  Bone       Date:  2010-12-17       Impact factor: 4.398

4.  Assessment of bone involvement in patients with multiple myeloma using bone densitometry.

Authors:  N Abildgaard; K Brixen; J E Kristensen; T Vejlgaard; P Charles; J L Nielsen
Journal:  Eur J Haematol       Date:  1996-11       Impact factor: 2.997

5.  Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens.

Authors:  T Vejlgaard; N Abildgaard; H Jans; J L Nielsen; L Heickendorff
Journal:  Eur J Haematol       Date:  1997-02       Impact factor: 2.997

6.  Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss.

Authors:  James R Berenson; Ori Yellin; Ralph V Boccia; Marshall Flam; Siu-Fun Wong; Olcay Batuman; Mehdi M Moezi; Donald Woytowitz; Herbert Duvivier; Youram Nassir; Regina A Swift
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

7.  Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma.

Authors:  M Laroche; M Attal; C Dromer
Journal:  Clin Rheumatol       Date:  1996-07       Impact factor: 2.980

8.  Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris. The Reykjavik Study.

Authors:  E Sigurdsson; G Thorgeirsson; H Sigvaldason; N Sigfusson
Journal:  Ann Intern Med       Date:  1995-01-15       Impact factor: 25.391

9.  The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance.

Authors:  Jessica Pepe; Maria Teresa Petrucci; Maria Lucia Mascia; Sara Piemonte; Valeria Fassino; Elisabetta Romagnoli; Salvatore Minisola
Journal:  Calcif Tissue Int       Date:  2008-06       Impact factor: 4.333

10.  Fracture risk assessment in older adults using a combination of selected quantitative computed tomography bone measures: a subanalysis of the Age, Gene/Environment Susceptibility-Reykjavik Study.

Authors:  Nahid J Rianon; Thomas F Lang; Kristin Siggeirsdottir; Gunnar Sigurdsson; Gudny Eiriksdottir; Sigurdur Sigurdsson; Brynjolfur Y Jonsson; Melissa Garcia; Binbing Yu; Asha S Kapadia; Wendell C Taylor; Beatrice J Selwyn; Vilmundur Gudnason; Lenore J Launer; Tamara B Harris
Journal:  J Clin Densitom       Date:  2013-04-02       Impact factor: 2.617

View more
  10 in total

1.  Use of trabecular bone score for risk stratification of patients with monoclonal gammopathy of undetermined significance.

Authors:  Jad G Sfeir; Tito D Pena Guzman; Lucia Bedatsova; Stephen M Broski; Matthew T Drake
Journal:  Bone       Date:  2020-04-28       Impact factor: 4.398

2.  Impact of whole-body vibration exercise on physical performance and bone turnover in patients with monoclonal gammopathy of undetermined significance.

Authors:  Lothar Seefried; Franca Genest; Johanna Strömsdörfer; Bernhard Engelmann; Constantin Lapa; Franz Jakob; Freerk T Baumann; Billy Sperlich; Franziska Jundt
Journal:  J Bone Oncol       Date:  2020-09-28       Impact factor: 4.072

Review 3.  Advanced Imaging of Multiple Myeloma Bone Disease.

Authors:  Barry G Hansford; Rebecca Silbermann
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-07       Impact factor: 5.555

4.  MGUS bone.

Authors:  Osamu Imataki; Makiko Uemura
Journal:  Oxf Med Case Reports       Date:  2019-08-28

Review 5.  Hematological Diseases and Osteoporosis.

Authors:  Agostino Gaudio; Anastasia Xourafa; Rosario Rapisarda; Luca Zanoli; Salvatore Santo Signorelli; Pietro Castellino
Journal:  Int J Mol Sci       Date:  2020-05-16       Impact factor: 5.923

Review 6.  Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All.

Authors:  Oliver C Lomas; Tarek H Mouhieddine; Sabrin Tahri; Irene M Ghobrial
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

Review 7.  Contributions of the Bone Microenvironment to Monoclonal Gammopathy of Undetermined Significance Pathogenesis.

Authors:  Beatriz Gámez; Claire M Edwards
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

8.  Dietary intake is associated with risk of multiple myeloma and its precursor disease.

Authors:  Marianna Thordardottir; Ebba K Lindqvist; Sigrun H Lund; Rene Costello; Debra Burton; Laufey Steingrimsdottir; Neha Korde; Sham Mailankody; Gudny Eiriksdottir; Lenore J Launer; Vilmundur Gudnason; Tamara B Harris; Ola Landgren; Johanna E Torfadottir; Sigurdur Y Kristinsson
Journal:  PLoS One       Date:  2018-11-01       Impact factor: 3.240

Review 9.  Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma.

Authors:  Michael H Tomasson; Mahmoud Ali; Vanessa De Oliveira; Qian Xiao; Yogesh Jethava; Fenghuang Zhan; Adam M Fitzsimmons; Melissa L Bates
Journal:  Int J Mol Sci       Date:  2018-11-16       Impact factor: 5.923

10.  Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort.

Authors:  Maxine Je Lamb; Alexandra Smith; Daniel Painter; Eleanor Kane; Timothy Bagguley; Robert Newton; Debra Howell; Gordon Cook; Ruth de Tute; Andrew Rawstron; Russell Patmore; Eve Roman
Journal:  BMJ Open       Date:  2021-02-22       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.